| Literature DB >> 35701516 |
Wei Hu1, Liang Zhou2, Jiadong Chu1, Na Sun1, Xuanli Chen1, Siyuan Liu1, Yueping Shen3.
Abstract
Although national health-related quality of life population norms had been published based on the EuroQol 5-Dimensions 5-levels scale, China is a vast country with diverse cultural and social development in various regions. Therefore, regional population norms may better reflect the health status of residents in a given area. The purpose of the study was to derive the HRQoL population norm for adult general population in southern Jiangsu Province using the EQ-5D-5L scale and explore potential influencing factors. The data were based on a cross-sectional survey conducted in Liyang City from March 2019 to July 2020. EQ-5D-5L utility scores based on Chinese value set and EQ-VAS scores were used to assess HRQoL. The Tobit regression model and generalized linear model were performed to identify the association among potential covariates and HRQoL. The means (95% confidence interval) of the EQ-5D-5L utility scores and EQ-VAS scores were 0.981(0.980-0.983) and 83.6(83.2-83.9), respectively. Younger people (≤ 40 years old) were more likely to experience problems with anxiety or depression. Additionally, women had lower HRQoL scores although multivariate analysis found no statistical difference between the sexes. Lower HRQoL was associated with advanced age, lower socioeconomic status, no spouse, lack of regular physical activities, smoking cessation, and chronic non-communicable diseases. Subjects who declared that they were afflicted by diseases presented significantly lower utility scores, ranging from 0.823 (0.766-0.880) for memory-related diseases to 0.978 (0.967-0.989) for hepatic diseases. Regional population norms of HRQoL are needed in the health economic study owing to the great socioeconomic differences across regions in China. The present study provides HRQoL population norms for adults in southern Jiangsu. These norm values could help policy makers better allocate limited health resources and prioritize service plans.Entities:
Mesh:
Year: 2022 PMID: 35701516 PMCID: PMC9198056 DOI: 10.1038/s41598-022-13910-x
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.996
EQ-5D-5L utility scores according to sample characteristics.
| Subject characteristics | EQ-5D-5L utility scores | ||
|---|---|---|---|
| n (%) | Mean (95%CI) | ||
| Overall | 10,056 | 0.981 (0.980–0.983) | |
| Male | 4734 (47.08) | 0.983 (0.981–0.985) | 0.001** |
| Female | 5322 (52.92) | 0.980 (0.978–0.982) | |
| 18–30 | 1407 (13.99) | 0.996 (0.994–0.998) | < 0.001** |
| 31–40 | 1699 (16.90) | 0.995 (0.993–0.997) | |
| 41–50 | 2408 (23.95) | 0.989 (0.987–0.991) | |
| 51–60 | 1905 (18.94) | 0.983 (0.980–0.986) | |
| 61–70 | 1411 (14.03) | 0.970 (0.966–0.973) | |
| 70 + | 1226 (12.19) | 0.941 (0.933–0.948) | |
| Urban | 778 (7.74) | 0.982 (0.980–0.983) | < 0.001** |
| Rural | 9278 (92.26) | 0.979 (0.975–0.983) | |
| Primary schools and below | 3087 (30.70) | 0.962 (0.959–0.966) | < 0.001** |
| Junior middle school | 3797 (37.76) | 0.986 (0.984–0.988) | |
| High school or similar | 1904 (18.93) | 0.993 (0.990–0.995) | |
| Junior College and above | 1268 (12.58) | 0.997 (0.996–0.998) | |
| A | |||
| < 50,000 | 2688 (26.73) | 0.959 (0.955–0.964) | < 0.001** |
| 50,000 | 3316 (32.98) | 0.986 (0.984–0.988) | |
| 100,000–149,999 | 2231 (22.19) | 0.992 (0.991–0.994) | |
| ≥ 150,000 | 1821 (18.11) | 0.993 (0.992–0.995) | |
| Retired/homemaker/unemployed/student | 2294 (22.81) | 0.962 (0.957–0.966) | < 0.001** |
| Paid employment | 7762 (77.19) | 0.987 (0.986–0.989) | |
| Married | 8464 (84.19) | 0.983 (0.981–0.984) | 0.017* |
| Unmarried/divorce/widow | 1589 (15.80) | 0.975 (0.971–0.979) | |
| Yes | 6128 (60.94) | 0.984 (0.982–0.985) | < 0.001** |
| No | 3927 (39.06) | 0.978 (0.975–0.981) | |
| Never | 7313 (72.72) | 0.981 (0.979–0.983) | < 0.001** |
| Current | 2452 (24.38) | 0.986 (0.983–0.988) | |
| Former | 291 (2.89) | 0.956 (0.942–0.970) | |
| Never | 7958 (79.14) | 0.981 (0.979–0.983) | 0.193 |
| Current | 2098 (20.86) | 0.983 (0.981–0.986) | |
| ≤ 23.9 | 5641 (56.10) | 0.983 (0.982–0.985) | < 0.001** |
| 24.0 to 27.9 | 3440 (34.21) | 0.980 (0.977–0.982) | |
| ≥ 28.0 | 975 (9.70) | 0.975 (0.970–0.980) | |
| 0 | 7638 (75.95) | 0.989 (0.988–0.990) | < 0.001** |
| 1 | 1738 (17.28) | 0.972 (0.968–0.976) | |
| ≥ 2 | 680 (6.76) | 0.922 (0.910–0.935) | |
**P < 0.001; * P < 0.05; # represents 3 missing data on marital status and 1 missing data on physical activity; CI confidence interval; BMI Body mass index; NCDs chronic non-communicable diseases; Paid employment, whether employed, full-time or part-time.
EQ-5D-5L utility scores for self-reported diseases with influencing HRQoL in men, women, and the total sample, respectively.
| Diseases | Total | Men | Women | ||||
|---|---|---|---|---|---|---|---|
| N | Mean (95%CI) | n | Mean (95%CI) | n | Mean (95%CI) | ||
| No self-reported diseases | 6858 | 0.994 (0.993–0.994) | 3205 | 0.994 (0.993–0.995) | 3653 | 0.993 (0.992–0.994) | 0.046* |
| Hypertension | 1815 | 0.959 (0.953–0.964) | 887 | 0.966 (0.959–0.973) | 928 | 0.952 (0.944–0.959) | < 0.001** |
| Diabetes mellitus | 499 | 0.951 (0.940–0.961) | 209 | 0.963 (0.949–0.977) | 290 | 0.941 (0.926–0.957) | 0.070 |
| Dyslipidemia | 325 | 0.947 (0.934–0.960) | 148 | 0.965 (0.953–0.977) | 177 | 0.932 (0.911–0.952) | 0.014* |
| Stroke | 185 | 0.854 (0.819–0.888) | 91 | 0.868 (0.818–0.918) | 94 | 0.839 (0.791–0.887) | 0.038* |
| CHD | 173 | 0.924 (0.905–0.944) | 80 | 0.934 (0.906–0.962) | 93 | 0.916 (0.888–0.943) | 0.173 |
| COPD | 114 | 0.923 (0.894–0.952) | 65 | 0.940 (0.902–0.977) | 49 | 0.901 (0.854–0.948) | 0.219 |
| Asthma | 77 | 0.890 (0.841–0.939) | 41 | 0.916 (0.854–0.978) | 36 | 0.861 (0.780–0.941) | 0.071 |
| Cancer | 110 | 0.959 (0.938–0.980) | 49 | 0.979 (0.967–0.990) | 61 | 0.943 (0.907–0.980) | 0.331 |
| Other respiratory diseases | 231 | 0.935 (0.918–0.952) | 135 | 0.941 (0.918–0.964) | 96 | 0.926 (0.900–0.952) | 0.202 |
| Hepatic diseases | 63 | 0.978 (0.967–0.989) | 38 | 0.982 (0.969–0.996) | 25 | 0.972 (0.952–0.992) | 0.275 |
| Cardiac diseases | 222 | 0.917 (0.898–0.936) | 104 | 0.927 (0.901–0.954) | 118 | 0.909 (0.881–0.936) | 0.196 |
| Kidney diseases | 66 | 0.942 (0.912–0.973) | 31 | 0.955 (0.929–0.981) | 35 | 0.931 (0.877–0.986) | 0.903 |
| Digestive system diseases | 791 | 0.946 (0.938–0.954) | 349 | 0.947 (0.935–0.959) | 442 | 0.945 (0.935–0.956) | 0.942 |
| Mental diseases | 116 | 0.880 (0.840–0.919) | 53 | 0.872 (0.798–0.947) | 63 | 0.886 (0.844–0.927) | 0.311 |
| Memory related diseases | 92 | 0.823 (0.766–0.880) | 43 | 0.795 (0.694–0.896) | 49 | 0.847 (0.783–0.911) | 0.833 |
| Arthritis | 530 | 0.921 (0.910–0.933) | 209 | 0.936 (0.921–0.952) | 321 | 0.912 (0.896–0.927) | 0.046 |
**P < 0.001; *P < 0.05; CI indicates confidence interval; EQ-5D-5L Euroqol-five dimensions-five levels; COPD chronic obstructive pulmonary disease; CHD coronary heart disease;
EQ-5D-5L norm utility scores according to sex.
| Variables | Men (N = 4734) | Women (N = 5322) | |||
|---|---|---|---|---|---|
| N (%) | mean(95%CI) | N (%) | mean(95%CI) | ||
| 18–30 | 689 (14.55) | 0.994 (0.990–0.998) | 718 (13.49) | 0.999 (0.998–1.000) | 0.056 |
| 31–40 | 769 (16.24) | 0.996 (0.994–0.997) | 930 (17.47) | 0.994 (0.991–0.997) | 0.340 |
| 41–50 | 1117 (23.60) | 0.990 (0.987–0.994) | 1291 (24.26) | 0.988 (0.986–0.991) | 0.008* |
| 51–60 | 928 (19.60) | 0.984 (0.980–0.988) | 977 (18.36) | 0.982 (0.979–0.986) | 0.177 |
| 61–70 | 656 (13.86) | 0.976 (0.971–0.980) | 755 (14.19) | 0.964 (0.958–0.971) | 0.011* |
| 70 + | 575 (12.15) | 0.947 (0.936–0.958) | 651( 12.23) | 0.936 (0.926–0.946) | 0.015* |
| Primary schools or below | 1189 (25.12) | 0.966 (0.960–0.971) | 1898 (35.66) | 0.960 (0.955–0.964) | 0.063 |
| Junior middle school | 1862 (39.33) | 0.985 (0.982–0.988) | 1935 (36.36) | 0.987 (0.985–0.990) | 0.805 |
| High school or similar | 1064 (22.48) | 0.991 (0.988–0.995) | 840 (15.78) | 0.995 (0.992–0.997) | 0.171 |
| Junior college and above | 619 (13.07) | 0.997 (0.996–0.998) | 649 (12.19) | 0.998 (0.997–0.999) | 0.849 |
| < 50,000 | 1228 (25.94) | 0.962 (0.956–0.969) | 1460 (27.43) | 0.957 (0.951–0.962) | 0.011* |
| 50,000 | 1521 (32.13) | 0.986 (0.984–0.989) | 1795 (33.73) | 0.985 (0.982–0.988) | 0.170 |
| 100,000–149,999 | 1076 (22.73) | 0.993 (0.991–0.995) | 1155 (21.70) | 0.991 (0.989–0.993) | 0.092 |
| ≥ 150,000 | 909 (19.20) | 0.994 (0.992–0.996) | 912 (17.14) | 0.992 (0.990–0.994) | 0.262 |
| < 18.5/18.5–23.9 | 2481 (52.41) | 0.984 (0.982–0.987) | 3160 (59.38) | 0.983 (0.980–0.985) | 0.774 |
| 24.0–27.9 | 1782 (37.64) | 0.982 (0.978–0.985) | 1658 (31.15) | 0.978 (0.975–0.981) | < 0.001** |
| ≥ 28.0 | 471 (9.95) | 0.983 (0.976–0.989) | 504 (9.47) | 0.968 (0.959–0.976) | < 0.001** |
**P < 0.001; *P < 0.05; CI confidence interval; BMI Body mass index.
EQ-5D-5L utility score by different domains of EQ-5D-5L scale.
| Domains | EQ-5D-5L Utility scores | |
|---|---|---|
| Mean (95%CI) | ||
| No problems | 0.989 (0.988–0.990) | < 0.001** |
| Problems | 0.662 (0.630–0.694) | |
| No problems | 0.987 (0.986–0.988) | < 0.001** |
| Problems | 0.589 (0.541–0.637) | |
| No problems | 0.989 (0.988–0.990) | < 0.001** |
| Problems | 0.677 (0.644–0.709) | |
| No problems | 0.997 (0.996–0.998) | < 0.001** |
| Problems | 0.864 (0.855–0.873) | |
| No problems | 0.990 (0.989–0.990) | < 0.001** |
| Problems | 0.816 (0.799–0.834) | |
| Problem-free | 1.000 | < 0.001** |
| At least a problem | 0.871 (0.863–0.878) | |
**P < 0.001; *P < 0.05; EQ-5D-5L Euroqol-five dimensions-five levels; EQ-VAS European quality of life-Visual Analogue Scale; CI confidence interval.
The incidence of self-reported health problems using the EQ-5D-5L descriptive system by age group and sex (%).
| Level | MO | SC | UA | PD | AD | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total | Men | Women | Total | Men | Women | Total | Men | Women | Total | Men | Women | Total | Men | Women | |
| No problems | 97.67 | 97.68 | 97.67 | 98.66 | 98.63 | 98.68 | 97.61 | 97.74 | 97.50 | 88.04 | 89.37 | 86.87 | 95.32 | 95.92 | 94.78 |
| Problems | 2.33 | 2.32 | 2.33 | 1.34 | 1.37 | 1.32 | 2.39 | 2.26 | 2.50 | 11.96 | 10.63 | 13.13 | 4.68 | 4.08 | 5.22 |
| No problems | 99.79 | 99.56 | 100.00 | 99.72 | 99.42 | 100.00 | 99.50 | 98.98 | 100.00 | 98.36 | 97.67 | 99.03 | 98.29 | 97.82 | 98.75 |
| Problems | 0.21 | 0.44 | 0.00 | 0.28 | 0.58 | 0.00 | 0.50 | 1.02 | 0.00 | 1.64 | 2.33 | 0.97 | 1.71 | 2.18 | 1.25 |
| No problems | 99.71 | 99.74 | 99.68 | 99.76 | 99.87 | 99.68 | 99.53 | 99.61 | 99.46 | 97.23 | 97.14 | 97.31 | 96.76 | 96.74 | 96.77 |
| Problems | 0.29 | 0.26 | 0.32 | 0.24 | 0.13 | 0.32 | 0.47 | 0.39 | 0.54 | 2.77 | 2.86 | 2.69 | 3.24 | 3.26 | 3.23 |
| No problems | 99.13 | 98.84 | 99.38 | 99.42 | 99.37 | 99.46 | 99.04 | 98.93 | 99.15 | 93.11 | 94.18 | 92.18 | 95.93 | 97.22 | 94.81 |
| Problems | 0.87 | 1.16 | 0.62 | 0.58 | 0.63 | 0.54 | 0.96 | 1.07 | 0.85 | 6.89 | 5.82 | 7.82 | 4.07 | 2.78 | 5.19 |
| No problems | 99.00 | 98.81 | 99.18 | 99.48 | 99.35 | 99.59 | 98.90 | 98.60 | 99.18 | 86.61 | 88.36 | 84.95 | 95.49 | 95.91 | 95.09 |
| Problems | 1.00 | 1.19 | 0.82 | 0.52 | 0.65 | 0.41 | 1.10 | 1.40 | 0.82 | 13.39 | 11.64 | 15.05 | 4.51 | 4.09 | 4.91 |
| No problems | 96.60 | 96.95 | 96.29 | 98.87 | 98.93 | 98.91 | 96.60 | 97.41 | 95.89 | 76.75 | 79.73 | 74.17 | 93.76 | 94.36 | 93.25 |
| Problems | 3.40 | 3.05 | 3.71 | 1.13 | 1.07 | 1.19 | 3.40 | 2.59 | 4.11 | 23.25 | 20.27 | 25.83 | 6.24 | 5.64 | 6.75 |
| No problems | 88.74 | 89.39 | 88.17 | 92.90 | 93.04 | 92.78 | 89.15 | 90.43 | 88.02 | 68.76 | 72.35 | 65.59 | 90.21 | 91.83 | 88.79 |
| Problems | 11.26 | 10.61 | 11.83 | 7.10 | 6.96 | 7.22 | 10.85 | 9.57 | 11.98 | 31.24 | 27.65 | 34.41 | 9.79 | 8.17 | 11.21 |
| 532.89 | 212.46 | 324.37 | 354.58 | 152.92 | 203.69 | 465.89 | 166.33 | 307.02 | 944.75 | 366.51 | 581.92 | 117.15 | 41.26 | 81.31 | |
| < 0.001 | < 0.001 | < 0.001 | < 0.001 | < 0.001 | < 0.001 | < 0.001 | < 0.001 | < 0.001 | < 0.001 | < 0.001 | < 0.001 | < 0.001 | < 0.001 | < 0.001 | |
Values are presented as percentages; MO mobility; SC self-care; UA usual activities; PD pain or discomfort; AD anxiety or depression.
Tobit regression analyses on the EQ-5D-5L utility scores.
| Variables | Coe | ||
|---|---|---|---|
| Male (Ref) | |||
| Female | − 0.006 | 0.011 | 0.585 |
| 18–30 (Ref) | |||
| 31–40 | − 0.054 | 0.022 | 0.015* |
| 41–50 | − 0.105 | 0.022 | < 0.001** |
| 51–60 | − 0.137 | 0.022 | < 0.001** |
| 61–70 | − 0.156 | 0.024 | < 0.001** |
| 70 + | − 0.195 | 0.024 | < 0.001** |
| Urban (Ref) | |||
| Rural | − 0.078 | 0.015 | < 0.001** |
| Primary schools and below (Ref) | |||
| Junior middle school | 0.044 | 0.010 | < 0.001** |
| High school or similar | 0.078 | 0.015 | < 0.001** |
| Junior College and above | 0.119 | 0.023 | < 0.001** |
| ≤ 50,000 (Ref) | |||
| 50,000 | 0.041 | 0.010 | < 0.001** |
| 100,000–149,999 | 0.062 | 0.013 | < 0.001** |
| ≥ 150,000 | 0.059 | 0.014 | < 0.001** |
| Retired/homemaker/unemployed/student (Ref) | |||
| Paid employment | 0.070 | 0.009 | < 0.001** |
| Married (Ref) | |||
| Unmarried/divorce/widow | − 0.040 | 0.012 | 0.001** |
| No (Ref) | |||
| Yes | 0.028 | 0.008 | 0.001** |
| Never (Ref) | |||
| Current | 0.003 | 0.013 | 0.837 |
| Former | − 0.065 | 0.021 | 0.001* |
| Never (Ref) | |||
| Current | − 0.005 | 0.011 | 0.637 |
| ≤ 23.9 (Ref) | |||
| 24.0 to 27.9 | − 0.008 | 0.009 | 0.340 |
| ≥ 28.0 | − 0.014 | 0.013 | 0.283 |
| 0 (Ref) | |||
| 1 | − 0.037 | 0.010 | < 0.001** |
| ≥ 2 | − 0.141 | 0.013 | < 0.001** |
**P < 0.001; *P < 0.05; EQ-5D-5L Euroqol-five dimensions-five levels; Ref the reference group; Coe coefficient; SE Standard error; BMI Body mass index; NCDs chronic non-communicable diseases; Paid employment, whether employed, full-time or part-time.